Changchun High-Tech's subsidiary gets approval for vaccine trial

Changchun High & New Technology Industry Group (SZSE:000661) announced that its subsidiary, Changchun Bai Ke Biotechnology, has received approval from the National Medical Products Administration to conduct clinical trials for its recombinant herpes zoster vaccine (CHO cells). The vaccine is designed for individuals aged 40 and above, aiming to stimulate immunity against the varicella-zoster virus and prevent herpes zoster. Bai Ke's vaccine uses the gE protein of the varicella-zoster virus and the company's innovative BK-02 adjuvant system. While the approval of the clinical trial is a positive step, the company cautioned that uncertainties remain regarding the successful commercialization of the vaccine. The company committed to disclosing information on the trial's progress.